On April 30, 2026 Krystal Biotech, Inc. (the "Company") (NASDAQ: KRYS) reported that the Company will be presenting on multiple programs at upcoming scientific conferences being held in May and June.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Presentation details are outlined below.
American Society of Gene & Cell Therapy (ASGCT) (Free ASGCT Whitepaper) 2026 Annual Meeting
Poster Presentation
Title: Evaluation of KB409 and KB410, two HSV-1-based gene therapy vectors for the treatment of primary ciliary dyskinesia (PCD)
Presenter: Bruce Nmezi, PhD
Date and Time: May 12, 2026 from 5:00PM to 6:30PM ET
American Thoracic Society (ATS) International Conference 2026
Oral Presentation
Title: Interim results of the CORAL-1 trial of KB407 for the treatment of cystic fibrosis
Presenter: Jorge Lascano, MD, Professor of Medicine, Associate Director of the Adult Cystic Fibrosis Program, and Director of the Cystic Fibrosis Therapeutics Development Center at the University of Florida
Date and Time: May 20, 2026 at 10:03AM ET
2026 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting
Poster Presentation
Title: Inhaled delivery of KB707, a novel HSV-based immunotherapy, in combination with pembrolizumab in advanced non-small cell lung cancer: a phase 1/2 study
Presenter: Wen Wee Ma, MBBS, Enterprise Vice Chair for Research and Director of the Novel Cancer Therapeutics Center at Cleveland Clinic Cancer Institute
Date and Time: May 31, 2026 from 9:00AM to 12:00PM CT
Additional presentation details will be available to conference attendees. Following completion of each conference, presentation slides or posters, as applicable, will also be available to view online on the Investor section of the Company’s website.
(Press release, Krystal Biotech, APR 30, 2026, View Source [SID1234664979])